Detalhe da pesquisa
1.
The subdued post-boost spike-directed secondary IgG antibody response in Ugandan recipients of the Pfizer-BioNTech BNT162b2 vaccine has implications for local vaccination policies.
Front Immunol
; 15: 1325387, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38469296
2.
Sustained S-IgG and S-IgA antibodies to Moderna's mRNA-1273 vaccine in a Sub-Saharan African cohort suggests need for booster timing reconsiderations.
Front Immunol
; 15: 1348905, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38357547
3.
The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort.
Front Immunol
; 15: 1384668, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38779677
4.
An Optimised Indirect ELISA Protocol for Detection and Quantification of Anti-viral Antibodies in Human Plasma or Serum: A Case Study Using SARS-CoV-2.
Bio Protoc
; 13(24): e4905, 2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38156036
5.
Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.
Front Immunol
; 14: 1183983, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37205095
6.
Sustained spike-specific IgG antibodies following CoronaVac (Sinovac) vaccination in sub-Saharan Africa, but increased breakthrough infections in baseline spike-naive individuals.
Front Immunol
; 14: 1255676, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38098482
7.
Pre-pandemic SARS-CoV-2-specific IFN-γ and antibody responses were low in Ugandan samples and significantly reduced in HIV-positive specimens.
Front Immunol
; 14: 1148877, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37153598
8.
Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months.
Front Immunol
; 14: 1152522, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37006272
9.
Spike protein is a key target for stronger and more persistent T-cell responses-a study of mild and asymptomatic SARS-CoV-2 infection.
Int J Infect Dis
; 136: 49-56, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37683720